Ademetionine for obstructive hypertrophic cardiomyopathy
Part of Heart & circulation clinical trials.
This trial tests a medication called Ademetionine for people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle is thick and blocks blood flow). It aims to see if the drug can help improve symptoms and exercise ability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of hypertrophic cardiomyopathy (HCM).
- You must be at least 18 years old.
- Your heart's pumping strength (ejection fraction) must be 50% or higher.
- You must have a significant pressure difference in your heart (30 mmHg or more) at rest or with activity.
- You should experience shortness of breath with mild activity or at rest (NYHA class II or III).
- You must be able to do a cardiopulmonary exercise test (CPET) and be willing to follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood samples from people with obstructive hypertrophic cardiomyopathy (a type of heart muscle disease) to explore how genetics and other factors affect how well the drug mavacamten works. It may help doctors better understand who benefits most from this treatment.
This study looks at how mavacamten (a heart medication) works for people with obstructive hypertrophic cardiomyopathy (HCM)—a condition where heart muscle becomes too thick. Researchers will review medical records and ask patients about their experiences with the treatment.
This trial tests a new treatment that uses radiofrequency energy (similar to heat) to shrink the thickened heart muscle blocking blood flow. It is for people with obstructive hypertrophic cardiomyopathy who have symptoms despite medication and are not able or willing to have heart surgery.
This study looks at how well mavacamten works in real life for adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is thickened and blocks blood flow. It may help improve symptoms like shortness of breath or chest pain.
This trial tests whether a drug called mavacamten can help people with a specific type of thickened heart muscle (obstructive hypertrophic cardiomyopathy, or oHCM) by improving how the heart uses energy. It aims to understand if this treatment can improve symptoms and function.
This trial tests a new drug, Aom0304, for people with hypertrophic cardiomyopathy (a condition where the heart muscle is thickened) who still have symptoms despite standard treatments. The study aims to see if the drug can improve symptoms and heart function.
Hear when a new Obstructive Hypertrophic Cardiomyopathy (oHCM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.